• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

    5/8/25 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMPX alert in real time by email
    • Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC).
      • Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting.
    • First patient dosed and actively enrolling patients in an Investigator Sponsored Trial (IST) evaluating tovecimig in patients with BTC in the first-line setting.
    • Successfully completed a pre-IND meeting for CTX-10726 (PD-1 x VEGF-A bispecific antibody), maintaining progress towards expected Q4 2025 IND filing and 2026 clinical data.
    • Advanced the Phase 1 dose-escalation study of CTX-8371 in a post-checkpoint inhibitor patient population to the fourth dosing cohort with no dose-limiting toxicities observed to date; data from this study are expected in the second half of 2025.
    • Ended Q1 with $113 million in cash and marketable securities, which is expected to provide cash runway into the first quarter of 2027.

    BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported first quarter 2025 financial results and provided a business update.

    "We're proud of the progress we've made this quarter, especially the achievement of the primary endpoint in our COMPANION-002 trial. These positive data reinforce the potential for tovecimig to fill a striking gap in the treatment paradigm for patients with BTC. We expect to share analyses of the secondary endpoints, including progression free survival (PFS), overall survival (OS) and duration of response (DoR), in the fourth quarter of this year," said Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors. "In parallel, the first patient has been dosed in the IST at The University of Texas MD Anderson Cancer Center evaluating tovecimig in the front-line setting for patients with BTC, and the study continues to actively enroll."

    "We continue to advance CTX-10726, our differentiated PD-1 x VEGF-A bispecific antibody, with IND filing expected in Q4. There has been very promising clinical data from other drugs in this class, and we look forward to beginning Phase 1 studies and reporting clinical data for CTX-10726 in 2026."

    "CTX-8371, our PD-1 x PD-L1 bispecific has also progressed to the fourth dosing cohort in patients in whom checkpoint inhibitors have failed, and we look forward to sharing data from the study later this year." Dr. Schuetz continued, "Finally, our balance sheet remains strong and we ended the quarter with $113 million, funding our cash runway into 2027."

    Development Pipeline Updates:

    Tovecimig (DLL4 and VEGF-A bispecific antibody)

    • Met the primary endpoint in the ongoing randomized Phase 2/3 COMPANION-002 Study in patients with BTC (see press release). The study enrolled 168 adult patients, randomized in a 2:1 ratio to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). 
      • Tovecimig in combination with paclitaxel achieved a 17.1% ORR, including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting.
      • At a prespecified analysis, conducted by blinded independent central radiology (BICR) review, tovecimig plus paclitaxel demonstrated a statistically significant (p=0.031) and clinically meaningful improvement in ORR (the primary endpoint) compared to paclitaxel alone.
      • The study also showed differences between treatment arms for other efficacy measures, including progressive disease (PD) rates of 16.2% in patients on tovecimig in combination with paclitaxel versus 42.1% in patients on paclitaxel alone.
      • The pre-specified number of events required to trigger the analyses of the secondary endpoints, including PFS, OS and DoR, has not yet been met due to fewer of these events occurring than were originally modeled. The Company expects to report the results of the analyses of these endpoints in Q4 of this year.
    • The first patient has been dosed in an IST at The University of Texas MD Anderson Cancer Center, and the study is actively enrolling. In the IST, tovecimig is being added to the standard first-line regimen of gemcitabine, cisplatin, and durvalumab (see press release).
    • The previously planned Phase 2 colorectal cancer study will be replaced by a Phase 2 basket study of tovecimig, which is expected to begin following the analyses of the secondary endpoint data from the COMPANION-002 BTC trial. The basket study will include a broader set of DLL4+ cancers, such as gastric, ovarian, renal, hepatocellular, and colorectal.



    CTX-10726 (PD-1 x VEGF-A bispecific antibody)

    • CTX-10726 is a tetravalent PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass. CTX-10726 is designed to synergistically deliver VEGF-A blockade and checkpoint inhibition, potentially applicable to multiple solid tumor indications. The bispecific antibody demonstrates a highly stable structure with high affinity target binding. CTX-10726 has exhibited more potent PD-1 blockade in preclinical studies, compared with data reported for other drugs in the class.
    • Advanced preclinical development and IND-enabling studies for CTX-10726.
    • Successfully completed a pre-IND Meeting with the FDA, with expected IND submission in Q4 2025.

    CTX-471 (CD137 agonist antibody)

    • CTX-471 is a CD137 agonist antibody, which has been shown to bind to a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity.
    • In 2024, CTX-471 clinical data were presented at multiple scientific meetings, including data demonstrating durable clinical responses in Phase 1 presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and data showing a correlation between levels of NCAM (CD56) expression and disease control presented at the 39th Society for Immunotherapy of Cancer 2024 Annual Meeting.
    • Phase 2 trial initiation of CTX-471 in patients with tumors expressing NCAM (CD56) is expected in the second half of 2025.

    CTX-8371 (PD-1 x PD-L1 bispecific antibody)

    • CTX-8371 is a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and has been shown to exhibit a unique mechanism-of-action that involves cleavage of cell surface PD-1.
    • No dose-limiting toxicities (DLTs) have been observed in the first three dosing cohorts in the Phase 1 dose-escalation study of CTX-8371.
    • Currently evaluating the fourth dosing cohort with preliminary data expected in the second half of 2025.

    Financial Results

    Net loss for the quarter ended March 31, 2025, was $16.6 million or $0.12 per share of common stock, compared to $10.8 million or $0.08 per share of common stock for the same period in 2024.

    Research and Development (R&D) Expenses

    R&D expenses were $13.1 million for the quarter ended March 31, 2025, as compared to $9.5 million for the same period in 2024, an increase of $3.6 million, or 37%. This increase was primarily attributable to additional spending on manufacturing for tovecimig and CTX-10726 of $2.5 million and $0.9 million on additional personnel costs for R&D personnel.

    General and Administrative (G&A) Expenses

    G&A expenses were $4.9 million for the quarter ended March 31, 2025, as compared to $3.2 million for the same period in 2024, an increase of $1.7 million or 51%. The increase was primarily attributable to $1.3 million of additional G&A personnel costs including $1.0 million related to share-based compensation.

    Cash Position 

    As of March 31, 2025, cash and marketable securities were $113 million as compared to $127 million as of December 31, 2024, providing the Company with an anticipated cash runway into 2027. During the first three months of 2025, $13 million of net cash was used in operating activities.

    About Compass Therapeutics

    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com. 

    Forward-Looking Statements

    This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass's financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass's product candidates, including their preclinical and clinical development and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans with respect to Compass's product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass's ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass's ability to identify additional product candidates for development, Compass's ability to develop, initiate and complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass's latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC.

    Investor Contact

    [email protected]

    Media Contact

    Anna Gifford, Chief of Staff

    [email protected]

    617-500-8099

     
    Compass Therapeutics, Inc. and Subsidiaries

    Condensed Consolidated Statements of Operations

    (In thousands, except per share data)
          
      Three Months Ended

    March 31,
     
       2025   2024  
      (unaudited) 
    Operating expenses:     
    Research and development $13,054  $9,522  
    General and administrative  4,912   3,248  
    Loss from operations  (17,966)  (12,770) 
    Other income  1,333   1,983  
    Net loss $(16,633) $(10,787) 
    Net loss per share - basic and diluted $(0.12) $(0.08) 
    Basic and diluted weighted average shares outstanding  138,236   136,608  
          



    Compass Therapeutics, Inc. and Subsidiaries

    Condensed Consolidated Balance Sheets

    (In thousands, except par value)
     
          
      March 31,

    2025
     December 31,

    2024
     
      (unaudited)   
    Assets     
    Current assets:     
    Cash and cash equivalents $41,048 $43,483 
    Marketable securities  71,587  83,239 
    Prepaid expenses and other current assets  11,510  6,029 
    Total current assets  124,145  132,751 
    Property and equipment, net  231  353 
    Operating lease, right-of-use ("ROU") asset  6,507  6,731 
    Other assets  568  568 
    Total assets $131,451 $140,403 
    Liabilities and Stockholders' Equity     
    Current liabilities:     
    Accounts payable $1,577 $2,249 
    Accrued expenses  13,214  6,287 
    Operating lease obligations, current portion  109  338 
    Total current liabilities  14,900  8,874 
    Operating lease obligations, long-term portion  6,272  6,296 
    Total liabilities  21,172  15,170 
    Total stockholders' equity  110,279  125,233 
    Total liabilities and stockholders' equity $131,451 $140,403 
          





    Primary Logo

    Get the next $CMPX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CMPX

    DatePrice TargetRatingAnalyst
    7/1/2025$9.00Outperform
    Raymond James
    4/2/2025$6.00Market Perform → Outperform
    Leerink Partners
    2/24/2025$12.00Buy
    Guggenheim
    2/19/2025$12.00Overweight
    Piper Sandler
    12/23/2024$32.00Buy
    D. Boral Capital
    11/15/2024$5.00 → $4.00Outperform → Market Perform
    Leerink Partners
    9/16/2024$5.00Neutral → Buy
    Ladenburg Thalmann
    1/31/2023$8.00Buy
    Jefferies
    More analyst ratings

    $CMPX
    SEC Filings

    See more
    • Compass Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Compass Therapeutics, Inc. (0001738021) (Filer)

      6/12/25 4:45:29 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

      SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      5/15/25 4:15:24 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Compass Therapeutics Inc.

      10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)

      5/8/25 8:01:09 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      5/27/25 3:24:21 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gordon Carl L sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/11/25 7:37:43 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Orbimed Advisors Llc sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/11/25 7:24:24 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

      BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat DetailsDate: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328 Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass' Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company devel

      5/28/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

      Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. First patient dosed and actively enrolling patients in an Investigator Sponsored Trial (IST) evaluating tovecimig in patients with BTC in the first-line setting.Successfully completed a pre-IND meeting for CTX-10726 (PD-1 x VEGF-A bispecific antibody), maintaining progress towards expected Q4 2025 IND filing and 2026 clinical data.Advanced the

      5/8/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics to Participate in Upcoming May Investor Events

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences ConferenceLocation: New York, NYDate: Thursday, May 8, 2025 Time: 1:30 PM ETWebcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQLocation: New York, NYDate: Tuesday, May 20, 2025 Time: 11:30AM ETWebcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3

      5/6/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

      BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa

      12/10/24 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Announces CEO Transition

      BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available

      5/28/24 4:10:20 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

      Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio

      5/4/23 8:30:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      11/14/24 10:00:35 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Compass Therapeutics Inc.

      SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

      8/2/24 4:15:57 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      3/22/24 4:59:51 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      5/27/25 3:24:21 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:30:55 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:25:57 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on Compass Therapeutics with a new price target

      Raymond James resumed coverage of Compass Therapeutics with a rating of Outperform and set a new price target of $9.00

      7/1/25 8:17:42 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Compass Therapeutics from Market Perform to Outperform and set a new price target of $6.00

      4/2/25 8:43:28 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Compass Therapeutics with a new price target

      Guggenheim initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00

      2/24/25 7:07:23 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Financials

    Live finance-specific insights

    See more
    • Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

      Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details:   Date:  May 04, 2022   Time: 8:00 a.m. ET   Webcast: Registration Link   Replay availability: A replay will be available on the Compass website for 6 months. Abo

      5/3/22 4:01:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OTC Markets Group Announces Quarterly Index Performance and Rebalancing

      NEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 3.9% in the second quarter. Ninety-two new companies were added to the index, including: AirBoss of America Corp. (OTCQX:ABSSF); Blackrock Silver Corp. (OTCQX:BKRRF); Belo Sun Mining Corp. (OTCQX:BSXGF); Caldwell Partners International Inc. (OTCQX:CWLPF); Graphite One Inc. (OTCQX:GPHOF)

      7/20/21 4:00:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care